Saving lives and accelerating innovation?
Antecedents and implications of the Expanded Access Programme in the pharmaceutical industry
Providing ‘investigational’ drugs to treat life-threatening conditions and severe diseases in developing countries through Expanded Access Programme (EAPs) could help save millions of lives – but raises obvious ethical and financial issues. This investigation examines the barriers that pharmaceutical firms face in releasing products through an EAP to better understand the challenges and identify ways for business to embrace innovation and corporate social responsibility. In doing so, it could help solve one of the most urgent global health challenges of our time.